. . . "approved"@en . . . "68302-57-8"@en . " "@en . "Amlexanox"@en . . . "# Bell J: Amlexanox for the treatment of recurrent aphthous ulcers. Clin Drug Investig. 2005;25(9):555-66. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17532700 "@en . . . . . . . . . . "Humans and other mammals"@en . . "Elimination half-life is 3.5 ± 1.1 hours."@en . . . . . "Amlexanox"@en . . . . . . . . . "investigational"@en . "No significant absorption directly through the active ulcer. Most of the systemic absorption is via the gastrointestinal tract."@en . . . . . . "2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid"@en . . "Amlexanoxo"@en . . . "Used as a paste in the mouth to treat aphthous ulcers (canker sores). "@en . "Amlexanoxum"@en . "Amoxanox"@en . . . . "Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population."@en . . . . . . . . "As a benzopyrano-bipyridine carboxylic acid derivative, amlexanox has anti-inflammatory and antiallergic properties. It inhibits chemical mediatory release of the slow-reacting substance of anaphylaxis (SRS-A) and may have antagonistic effects on interleukin-3. When cells are under stress, they release an inactive form of human fibroblast growth factor 1 (FGF-1), a potent mitogen (entity that causes mitosis). Amlexanox binds to FGF1, increasing its conformational stability, sterically blocking Cu(2+) induced oxidation which normally leads to activation of FGF-1. "@en . .